Trial Profile

Natalizumab (Tysabri) High Resolution MRI and Clinical Immunology-Correlative Observational Study in Multiple Sclerosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms THRIFT-MS
Sponsors Biogen

Most Recent Events

23 Dec 2014 Accrual to Date is 100 % according to the United Kingdom Clinical Research Network record.
23 Dec 2014 Planned number of patients changed from 18 to 40 as reported by United Kingdom Clinical Research Network record.
23 Dec 2014 Planned End Date changed from 31 Jan 2015 to 16 Oct 2014 as reported by United Kingdom Clinical Research Network record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com